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Abstract
The concept of healthcare-associated infections (as opposed to hospital-acquired infec-
tions) in intraabdominal infections (IAIs) is scarcely supported by data in the literature. The
aim of the present study was to analyse community-onset IAIs (non-postoperative/non-nos-
ocomial) in patients admitted to intensive care units (ICUs), to investigate differences in
resistance patterns linked to healthcare exposure and mortality-associated factors. A one-
year prospective observational study (17 Spanish ICUs) was performed distributing cases
as healthcare-associated infections (HCAI), community-acquired infections (CAI) and
immunocompromised patients (ICP). Bacteria producing extended-spectrum β-lactamases
(ESBL) and/or carbapenemase (CPE), high-level aminoglycoside- and/or methicillin- and/or
vancomycin- resistance were considered antimicrobial resistant (AMR). Mortality-associ-
ated factors were identified by regression multivariate analysis. Of 345 patients included
(18.8% HCAI, 6.1% ICP, 75.1% CAI), 51.6% presented generalized peritonitis; 32.5% were
>75 years (55.4% among HCAI). Overall, 11.0% cases presented AMR (7.0% ESBL- and/or
CPE), being significantly higher in HCAI (35.4%) vs. CAI (5.8%) (p<0.001) vs. ICP (0%) (p =
0.003). Overall 30-day mortality was 14.5%: 23.1% for HCAI and 11.6% for CAI (p = 0.016).
PLOS ONE | https://doi.org/10.1371/journal.pone.0223092 September 26, 2019 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Maseda E, Ramı́rez S, Picatto P, Peláez-
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Mortality (R2 = 0.262, p = 0.021) was positively associated with age >75 years (OR = 6.67,
95%CI = 2.56–17.36,p<0.001), Candida isolation (OR = 3.05, 95%CI = 1.18–7.87,p =
0.022), and SAPS II (per-point, OR = 1.08, 95%CI = 1.05–1.11, p<0.001) and negatively
with biliary infections (OR = 0.06, 95%CI = 0.01–0.48,p = 0.008). In this study, the antimicro-
bial susceptibility pattern of bacteria isolated from patients with healthcare contact was
shifted to resistance, suggesting the need for consideration of the healthcare category (not
including hospital-acquired infections) for severe IAIs. 30-day mortality was positively
related with age >75 years, severity and Candida isolation but not with AMR.
Introduction
Complicated intra-abdominal infections (IAIs) are severe infections requiring early adequate
empirical treatment in addition to control of infectious foci. Approximately 40% of all patients
diagnosed with secondary peritonitis need ICU treatment [1], IAIs being the second most
common cause of sepsis [2]. Reported mortality rates of severe secondary peritonitis have only
slightly decreased over the last decades, and range from 20% to 60% [1,3], thus remaining as
an important field for research. The increasingly advanced age of the population (with the
associated burden of chronic diseases), and the increased diagnosis in patients with impaired
host defences complicate even more outcomes and increase mortality [3,4].
Since there is general agreement on the prime importance of controlling early source to
reduce mortality [4–6], nowadays, the focus is on improving early empirical antimicrobial
treatments. Inadequate empirical treatments are those providing inadequate coverage of the
potential microorganisms involved, their resistance traits being of special importance. For
complicated IAIs, the traditional binary classification (in-/out-hospital patient) may be not
fully resolute for identification of patients at risk for antibiotic-resistant infections since non-
hospitalized patients having contact with healthcare settings may be nonetheless at risk. Fur-
thermore, resistant isolates are increasingly being isolated from patients without risk factors
for healthcare/hospital- acquired infections [4,7,8], this representing a challenge for selecting
initial antibiotic treatment.
The AGORA initiative [9] and the 2017’s guidelines by The Surgical Infection Society [4]
differentiate community-acquired IAIs and healthcare-associated IAIS, with presumed differ-
ences in resistance patterns between both categories [9]. But in both documents, hospital-
acquired infections are considered as part of healthcare-associated infections [4,9]. In IAIs the
concept of healthcare-associated infections as opposed to hospital-acquired infections (unlike
what occurs for bacteraemia and pneumonia) is scarcely supported by published data [10]
and, traditionally, it is not considered a category different from nosocomial and community-
acquired IAIs [11]. However, in contrast to the widely described resistance in pathogens
responsible of nosocomial IAIs [12,13], there are few data from healthcare-associated and
community-acquired IAIs to help in identifying risks factors for infections by resistant patho-
gens [4]. In addition, if the presence of multi-drug resistant bacteria implies higher severity, as
it occurs for other pathologies [14], needs also further clarification.
We designed the prospective observational multicentre HELP study to describe characteris-
tics of IAIs having community-onset (i.e, non-postoperative/non-nosocomial), in patients that
due to their severity required ICU management, to investigate possible differences in antibiotic
resistance patterns between patients with and without healthcare exposure, and factors associ-
ated with mortality.
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Material and methods
The HELP study (HELP = HEaLthcare-associated intra-abdominal infections study in criti-
cally ill Patients) was a prospective, observational, multicentre study conducted in 17 ICUs in
Spanish Universitary hospitals. These centres included all consecutive adult patients (�18 yr),
admitted in the ICU after surgical treatment for control of the infectious foci, having as diag-
nosis non-postoperative/non-nosocomial IAIs. All patients must have an intraoperative
microbiological sample (peritoneal fluid) collected for culture. The study included patients
entering the ICUs between November 1st 2014 and October 31th 2015. IAIs following surgery
(post-operative) or those diagnosed in patients admitted for�48 hours (nosocomial) were
excluded. The study protocol was approved by the Ethics Committee of Hospital La Paz,
Madrid, Spain. Participants were asked to sign a written consent at entry in the ICU. The
study was performed in accordance with the ethical standards laid down in the Declaration of
Helsinki (Edinburgh, October 2000).
Patients were divided in three groups: patients with healthcare-associated infections
(HCAI), patients with community-acquired infections (CAI) and immunocompromised
patients (ICP). HCAI was defined as an infection in patients with at least one of the following
criteria: i) Hospitalization in an acute care hospital for�48 hours within 90 days prior to the
onset of infection, ii) Residence in nursing homes or extended-care facilities, iii) Home infu-
sion therapy including antibiotics, iv) Chronic dialysis within 30 days prior to the onset of
infection, v) Domiciliary wound care, and/or vi) Family member carrying multidrug-resistant
pathogens [15]. ICP were considered patients with immunosuppressive treatment, chemother-
apy, corticosteroid therapy for at least 4 weeks before onset of infection, solid organ transplant,
and/or HIV-positive patients [15]. IAIs that did not fill exclusion criteria and criteria for
HCAI or ICP were considered CAI. Patients presenting criteria for classification as ICP and
HCAI were assigned to the HCAI group.
Demographic, clinical and microbiological data, empirical antimicrobial treatment, compli-
cations, length of stay, and outcome (mortality in the ICU and 30-day mortality) were
recorded. Adequacy of source control was evaluated considering criteria previously described
[16]. The previous functional status (Barthel index) [17], the Sequential Organ Failure Assess-
ment (SOFA) [18] and the Simplified Acute Physiologic Score-II (SAPS II) [19] scores were
calculated using clinical data at ICU admission. Blood and intraoperative intra-abdominal
fluid samples were collected and immediately sent to the Microbiology laboratory of each cen-
tre for processing following standard methods in daily practice. Isolated bacteria presenting
extended-spectrum β-lactamases (ESBL) and/or carbapenemase production (for gram-nega-
tives) and/or high-level aminoglycoside resistance (HLAR) and/or resistance to vancomycin
and/or methicillin resistance (for gram-positives) were considered antimicrobial resistant
pathogens (AMR).
Differences between groups were assessed by t-test or U-Mann-Whitney non-parametric
tests (continuous variables) or by Chi square/Fisher exact tests (discrete variables). For the
comparisons between the three groups (HCAI, CAI and ICP), due to the multiple comparisons
performed, the Bonferroni correction was applied and the resulting level of significance was
rounded down and set at p� 0.01. A stepwise logistic regression multivariate analysis was con-
ducted in order to determine variables associated with 30-day mortality. All variables showing
differences in the two-group data (survivors/dead) analyse (p<0.05) were included. Interac-
tions and linear dependence between independent variables were previously controlled. The
significant model (p<0.05) showing the maximum parsimony (the lowest number of variables
without significant reduction in the value of the determination coefficient) and the highest R2
was considered. All statistical calculations were computed using SPSS v.14.
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Results
A total of 360 outpatients with IAIs (non-postoperative/non-nosocomial) were considered in
the 17 participating ICUs during the one-year study period. Fifteen were excluded due to miss-
ing data, and 345 patients remained as evaluable for the study analysis. Of them, 18.8% (65 out
of 345) were HCAI cases, 6.1% (21 out of 345) were ICP cases, and the remaining 75.1% (259
out of 345) were cases of CAI. Up to 51.6% patients presented generalized peritonitis, without
difference by groups. Table 1 shows demographic data by type of infection. Source control was
considered adequate in 311 (90.1%) cases, without differences by study group. Colon was the
most frequent infection site in all groups: up to ~62% cases among ICPs, a percentage higher
than for CAI (32.8%) (p = 0.007). Patients with HCAI presented significantly higher mean age
(p<0.001) and abscess formation (p = 0.004) while patients with CAI presented higher per-
centage of infections involving the appendix compared to HCAI (p<0.001).
Table 2 shows comorbidities, severity scores and complications by type of infection. Signifi-
cantly higher percentages of patients with congestive heart disease, chronic renal failure, and
malignancies were found in the HCAI versus CAI groups; values of SAPS II and SOFA were
also higher (p<0.001). Malignancies and liver disease were more frequent among ICP versus
CAI cases (p<0.001). Septic shock was the most frequent complication in all groups, being sig-
nificantly more frequent in HCAI (>50% cases) than in CAI.
Only 10.7% patients presented positive blood culture; among them, the most frequent iso-
late was E. coli (3.2%), without differences between groups. Among bacteria isolated from peri-
toneal fluid, the percentage of AMR was 11.0%, being 7.0% for ESBL- and/or carbapenemase-
producing enterobacteria. Overall, the percentage of AMR was significantly higher in HCAI
Table 1. Demographic and clinical data.
Variable HCAIa (n = 65) CAIa (n = 259) ICPa (n = 21)
p vs. HCAI p vs. HCAI p vs. CAI
Age (years; mean ± SD) 72.5 ± 15.2 62.3 ± 17.5 <0.001 61.0 ± 16.2 ns ns
Age >75 years [n (%)] 36 (55.4) 72 (27.8) <0.001 4 (19.0) 0.003 ns
Males 35 (53.8) 143 (55.2) ns 13 (61.9) ns ns
Days in hospital pre-ICU admission (mean ± SD) 2.3 ± 8.4 0.6 ± 0.9 ns 1.0 ± 1.5 ns ns
Adequate control of infectious foci 58 (89.2) 236 (91.1) ns 17 (81.0) ns ns
Site of infection
Stomach 9 (13.8) 47 (18.1) ns 0 (0.0) ns ns
Small bowel 13 (20.0) 28 (10.8) ns 2 (9.5) ns ns
Biliary tract 18 (27.7) 43 (16.6) ns 3 (14.3) ns ns
Appendix 2 (3.1) 56 (21.6) <0.001 3 (14.3) ns ns
Colon 23 (35.4) 85 (32.8) ns 13 (61.9) ns 0.007
Type of infection/process
Generalized peritonitis 32 (49.2) 131 (50.6) ns 15 (71.4) ns ns
Localized peritonitis 15 (23.1) 83 (32.0) ns 3 (14.3) ns ns
Abscess 12 (18.5) 18 (6.9) 0.004 0 (0.0) ns ns
GIb perforation 6 (9.2) 27 (10.4) ns 3 (14.3) ns ns
Negative peritoneal culture 7 (10.5) 48 (18.5) ns 0 (0.0) ns ns
Demographic and clinical data by type of peritonitis. Data expressed as n (%) except where indicated
aHCAI: Healthcare-associated infection; CAI: Community-associated infection; ICP: Immunocompromised patients
bGI: Gastro-intestinal
ns: non-significant (p>0.01)
https://doi.org/10.1371/journal.pone.0223092.t001
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(23/65; 35.4%) vs. CAI (15/259; 5.8%) (p<0.001) or vs. ICP (0/21; 0%) (p = 0.003), without dif-
ferences between CAI and ICP (p = 0.641).
Table 3 shows per species percentage of isolation of aerobic/facultative bacteria from perito-
neal fluid. Isolation of ESBL-and/or carbapenemase- producing bacteria was significantly
more frequent from HCAI than CAI patients (p<0.001), with significant higher percentages of
ESBL-producing E. coli (p = 0.030) and Klebsiella spp. (p = 0.001). These type of isolates were
not found among enterobacteria isolated from ICP patients. Isolation of enterococci was sig-
nificantly more frequent from HCAI than CAI (33.8% vs. 17.8%, p = 0.004), with higher per-
centage of isolates showing HLAR [9 out of 22 (40.9%) vs. 3 out of 46 (6.5%) for HCAI vs. CAI
isolates].
No differences in total gram-negative anaerobic bacteria isolation were found between
groups. ICP patients presented significantly higher rates of Clostridium spp. isolation com-
pared with patients with CAI (23.8% vs. 4.7%; p = 0.005). Overall, isolation of Candida spp.
occurred in 19.1% (66 out of 345) patients, without differences between groups (23.1% for
HCAI, 17.8% for CAI and 23.8% for ICP).
Table 4 shows empirical antimicrobial treatment by group. Piperacillin-tazobactam was sig-
nificantly more frequent as empirical treatment in CAI than in ICP (p = 0.008), while the use
of carbapenems (and among them, meropenem) was significantly more frequent in ICPs vs.
HCAI or CAI (p<0.01). Treatment with tigecycline and daptomycin was significantly more
Table 2. Comorbidities, severity scores and complications.
Variable HCAIa (n = 65) CAIa (n = 259) ICPa (n = 21)
p vs. HCAI p vs. HCAI p vs. CAI
Barthel index (mean ± SD) 71.8 ± 24.9 89.3 ± 13.1 <0.001 85.2 ± 12.2 0.007 ns
Comorbidities
Congestive heart disease 12 (18.5) 10 (3.9) <0.001 3 (14.3) ns ns
Chronic Obstructive Pulmonary Disease 8 (12.3) 31 (12.0) ns 0 (0.0) ns ns
Diabetes mellitus 13 (20.0) 42 (16.2) ns 3 (14.3) ns ns
Liver disease 3 (4.6) 12 (3.6) ns 6 (28.6) 0.002 <0.001
Chronic renal failure 12 (18.5) 16 (6.2) 0.001 3 (14.3) ns ns
Alcoholism 11 (16.9) 26 (10.0) ns 3 (14.3) ns ns
Malignancies 17 (26.2) 30 (11.6) 0.003 9 (42.9) ns <0.001
Severity (mean ± SD)
SAPS IIb 46.6 ± 14.7 37.0 ± 16.0 <0.001 42.3 ± 17.4 ns ns
Sequential Organ Failure Assessment (SOFA) 6.3 ± 3.1 4.2 ± 3.6 <0.001 6.3 ± 2.5 ns ns
Lactate (mmol/l) 2.5 ± 2.8 2.4 ± 2.2 ns 2.4 ± 2.2 ns ns
Complications
Acute respiratory distress syndrome 4 (6.2) 18 (6.9) ns 0 (0.0) ns ns
Mechanical ventilation >24h 20 (30.8) 54 (20.8) ns 8 (38.1) ns ns
Noninvasive mechanical ventilation>24h 7 (10.8) 29 (11.2) ns 1 (4.8) ns ns
Septic shock 33 (50.8) 79 (30.5) 0.002 12 (57.1) ns ns
Disseminated intravascular coagulation 4 (6.2) 11 (4.2) ns 0 (0.0) ns ns
Acute renal failure 24 (36.9) 70 (27.0) ns 9 (42.9) ns ns
Renal replacement therapy 4 (6.2) 19 (7.3) ns 3 (14.3) ns ns
Comorbidities, severity scores and complications. Data expressed as n (%) except where indicated
aHCAI: Healthcare-associated infection; CAI: Community-associated infection; ICP: Immunocompromised patients
bSAPS II: Simplified Acute Physiologic Score-II
ns: non-significant (p>0.01)
https://doi.org/10.1371/journal.pone.0223092.t002
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frequent in HCAI and ICP than in CAI patients. Antifungals were used in a total of 13%
patients, without differences between groups.
Table 5 shows length of stay and outcome by type of infection. No differences in the vari-
ables analysed were found between groups. In the subgroup of patients >75 years (n = 112),
no significant differences (p = 0.452) in 30-day mortality were found between groups: 12/36
(33.3%) for HCAI; 19/72 (26.4%) for CAI and 0/4 for ICP.
The ICP group was excluded from the multivariate analysis due to its low number of
patients, remaining 324 patients (279 surviving and 45 dead patients). Variables showing dif-
ferences in the two-group data analysis (those included in the multivariate analysis) are shown
in Table 6. Different models were performed. The Hosmer-Lemeshow test and the perfor-
mance of the models were evaluated, being always<0.01. The significant (p<0.05) model
showing the maximum parsimony and the highest R2 (R2 = 0.262, p = 0.021) indicated age
>75 years (OR = 6.67, 95%CI = 2.56–17.36, p<0.001), Candida isolation from peritoneal fluid
(OR = 3.05, 95%CI = 1.18–7.87, p = 0.022), and SAPS II (per point, OR = 1.08, 95%CI = 1.05–
1.11, p<0.001) as variables positively associated with mortality, and biliary tract as site of
Table 3. Microbiological data.
Bacteria HCAIa (n = 65) CAIa (n = 259) ICPa (n = 21)
p vs. HCAI p vs. HCAI p vs. CAI
Total Enterobacteria 48 (73.8) 169 (65.3) ns 17 (81.0) ns ns
E. coli (Total) 31 (47.7) 119 (45.9) ns 13 (61.9) ns ns
E. coli (ESBLb) 5 (7.7) 5 (1.9) ns 0 (0.0) 0.009 ns
E. coli (CPEc) 2 (3.1) 2 (0.8) ns 0 (0.0) ns ns
Klebsiella spp (Total) 11 (16.9) 33 (12.7) ns 3 (14.3) ns ns
Klebsiella spp (ESBLb) 4 (6.2) 0 (0.0) 0.001 0 (0.0) ns ns
Klebsiella spp (CPEc) 1 (1.5) 0 (0.0) ns 0 (0.0) ns ns
Enterobacter spp (Total) 3 (4.6) 11 (4.2) ns 1 (4.8) ns ns
Enterobacter spp (ESBLb) 1 (1.5) 4 (1.5) ns 0 (0.0) ns ns
Total ESBLb enterobacteria 10 (15.4) 9 (3.5) 0.001 0 (0.0) ns ns
Total CPEc 3 (4.6) 2 (0.8) ns 0 (0.0) ns ns
Total ESBLb and/or CPEc 13 (20.0) 11 (4.2) <0.001 0 (0.0) ns ns
Pseudomonas spp. 1 (1.5) 16 (6.2) ns 3 (14.3) ns ns
Total gram-positive bacteria 39 (60.0) 112 (43.2) ns 7 (33.3) ns ns
Total Enterococcus 22 (33.8) 46 (17.8) 0.004 2 (9.5) ns ns
E. faecalis 5 (7.7) 17 (6.6) ns 1 (4.8) ns ns
E. faecium (Total) 11 (16.9) 16 (6.2) 0.005 1 (4.8) ns ns
E. faecium (HLARd) 6 (9.2) 1 (0.4) <0.001 0 (0.0) ns ns
Enterococcus spp. (Total) 6 (9.2) 13 (5.0) ns 0 (0.0) ns ns
Enterococcus spp. (HLARd) 3 (4.6) 2 (0.8) ns 0 (0.0) ns ns
Enterococcus spp. (vancomycin-resistant) 1 (1.5) 1 (0.4) ns 0 (0.0) ns ns
Total HLARd bacteria 9 (13.8) 3 (1.2) <0.001 0 (0.0) ns ns
Per species, percentage of isolation of aerobe/facultative bacteria from peritoneal fluid. Data are expressed as n (%).
aHCAI: Healthcare-associated infection; CAI: Community-associated infection; ICP: Immunocompromised patients
bESBL: extended spectrum β-lactamase-producing
cCPE: carbapenemase-producing
dHLAR: High-level aminoglycoside resistance
ns: non-significant ns: non-significant (p>0.01)
https://doi.org/10.1371/journal.pone.0223092.t003
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infection (OR = 0.06, 95%CI = 0.01–0.48, p = 0.008) as variable negatively associated with
mortality.
Discussion
Up to 17 Spanish UCIs participated in this observational study analysing severe IAIs having
community-onset. Our results confirm for this entity the difference of resistance patterns in
community patients with and without healthcare exposure, since isolation of AMR from
Table 4. Antimicrobial treatment.
Antimicrobials HCAIa (n = 65) CAIa (n = 259) ICPa (n = 21)
p vs. HCAI p vs. HCAI p vs. CAI
Total β-lactams 62 (0.95) 266 (1.03) ns 22 (1.05) ns ns
Penicillins (Total) 33 (0.51) 165 (0.64) ns 6 (0.29) ns 0.001
Amoxicillin/clavulanic acid 5 (0.08) 56 (0.22) ns 0 (0.00) ns ns
Piperacillin/tazobactam 28 (0.43) 109 (0.42) ns 6 (0.29) ns 0.008
Cephalosporins (Total) 4 (0.06) 21 (0.08) ns 2 (0.10) ns ns
Cefotaxime 3 (0.05) 18 (0.07) ns 1 (0.05) ns ns
Ceftriaxone 1 (0.02) 2 (0.01) ns 1 (0.05) ns ns
Ceftazidime 0 (0.00) 1 (0.00) ns 0 (0.00) - ns
Carbapenems (Total) 23 (0.35) 79 (0.31) ns 14 (0.67) ns 0.001
Imipenem 1 (0.02) 15 (0.06) ns 1 (0.05) ns ns
Meropenem 17 (0.26) 35 (0.14) ns 12 (0.57) 0.009 <0.001
Ertapenem 5 (0.08) 29 (0.11) ns 1 (0.05) ns ns
Monobactams (Aztreonam) 2 (0.03) 1 (0.00) ns 0 (0.00) ns ns
Total aminoglycosides 4 (0.06) 15 (0.06) ns 2 (0.10) ns ns
Total quinolones 2 (0.03) 5 (0.02) ns 1 (0.05) ns ns
Glycylcyclines (Tigecycline) 9 (0.14) 7 (0.03) <0.001 3 (0.14) ns 0.006
Daptomycin 4 (0.06) 2 (0.01) 0.004 2 (0.10) ns 0.001
Linezolid 4 (0.06) 16 (0.06) ns 4 (0.19) ns ns
Metronidazole 7 (0.11) 27 (0.10) ns 3 (0.14) ns ns
Total antifungals 10 (0.15) 29 (0.11) ns 6 (0.29) ns ns
Antimicrobials used as empirical treatment. Data are expressed as n (ratio of per-patient antimicrobial use).
aHCAI: Healthcare-associated infection; CAI: Community-associated infection; ICP: Immunocompromised patients
ns: non-significant (p>0.01)
https://doi.org/10.1371/journal.pone.0223092.t004
Table 5. Length of stay and outcome in the ICU.
Variable HCAIa (n = 65) CAIa (n = 259) ICPa (n = 21)
p vs. HCAI p vs. HCAI p vs. CAI
Length of stay in the ICU [days; median (IQR)] 4.0 (1.0–7.0) 2.0 (1.0–6.0) ns 5.0 (1.0–8.5) ns ns
Length of hospital stay [days; median (IQR)] 17.0 (10.5–27.0) 12.0 (8.0–24.0) ns 19.0 (13.0–46.5) ns ns
Mortality in the ICU [n (%)] 3 (4.6) 21 (8.1) ns 4 (19.0) ns ns
Mortality within 30 days of infection onset [n (%)] 15 (23.1) 30 (11.6) ns 5 (23.8) ns ns
Length of stay and outcome by type of peritonitis
aHCAI: Healthcare-associated infection; CAI: Community-associated infection; ICP: Immunocompromised patients
IQR: Interquartile range
ns: non-significant (p>0.01)
https://doi.org/10.1371/journal.pone.0223092.t005
Impact of resistance in community-onset severe intraabdominal infections
PLOS ONE | https://doi.org/10.1371/journal.pone.0223092 September 26, 2019 7 / 12
peritoneal fluid was significantly more frequent from HCAI versus CAI. However, in the mul-
tivariate analysis no association between AMR and 30-day mortality was found. On the con-
trary, our 30-day mortality was positively associated with age>75 years, Candida isolation
from peritoneal fluid, and values of SAPS II, and negatively associated with biliary tract as site
of infection.
Therapeutic recommendations are based, among others, on the severity of the infection,
age, patient’s status captured by scoring systems [4,20], and the possibility of multidrug resis-
tant bacteria in relation to the origin of the infection [4,21]. In the present study, the different
characteristics of patients in the study groups were in line with all these criteria: patients with
healthcare exposure were significantly older, presented higher severity at admission, and pre-
sented more frequently AMR than CAI cases. Therefore, from the microbiological perspective
(AMR), our results validate the category of healthcare-associated IAIs as opposed to commu-
nity infections. This constitutes the main difference with other studies investigating risk factors
for IAIs by multidrug resistant pathogens which considered hospital-acquired infections
among healthcare-associated infections [22,23].
The profile of pathogens isolated from peritoneal samples was in accordance with previous
studies, with similar percentages of enzymatic resistance in enterobacteria (20% for HCAI and
4.2% for CAI) [24,25], and isolation rates of enterococci significantly higher in HCAI than
CAI, as in a previous study on community-onset healthcare-associated IAIs [26]. An interest-
ing finding was the low rate of non-fermenters found, probably in relation to the community-
onset of infections, since additional pathogenic bacteria as P. aeruginosa and yeasts must be
considered in hospital-associated complicated IAIs and in immunocompromised hosts [27].
The reduced number of ICP patients limited its analysis, not allowing for drawing conclusions.
Candida spp. was the third most frequent microorganism isolated after E. coli and enterococci,
without differences in isolation rates between HCAI and CAI. The overall percentage of Can-
dida isolation in our study was high, and similar to the percentage found in critically ill
patients with secondary and tertiary abdominal sepsis [28]. Nevertheless, postoperative perito-
nitis has different microbiological features than non-postoperative nosocomial IAIs and CAIs,
where the similar frequency of yeast isolation has been reported [29].
Surprisingly, AMR (as defined in the present study) were not isolated from ICP patients,
possibly due to the reduced number of ICP cases included. But, on the contrary, AMR were
found in 5.8% of the patients not having contact with healthcare, thus, theoretically, not pre-
senting risk factors for harbouring resistant bacteria. In this sense, the lack of difference in iso-
lation of ESBL-producing E. coli between HCAI and CAI illustrates the extension of the risk
for resistance beyond the healthcare settings to the community. The presence of resistant E.
coli isolates in the community is increasing over time, as confirmed in the SMART Program,
where the rate of multidrug-resistant E. coli was more than double from 2009 to 2013 among
community-associated IAIs [30].
In the present study, overall mortality was similar to the one described in other studies on
non-post-operative intraabdominal infections [31,32]. The multivariate analysis did not iden-
tify AMR as variable associated with 30-day mortality. A previous study in ICU-acquired
bloodstream infections showed similar results, the pathogen resistance pattern not impacting
attributable mortality [33]. In our study, the 30-day mortality relied on other classical parame-
ters as advanced age and severity, and microbiological parameters as isolation of Candida spp.
Nevertheless, despite its statistical significance, interpretations of these results need caution
since for age a substantial OR value was accompanied by a large confidence interval, and for
SAPS II the magnitude of effect was an OR = 1.08 per point increased in the score. However,
our results are well supported by the literature. In a previous study on acute secondary perito-
nitis, age older than 80 years showed to be an independent risk factor of mortality regardless
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the Mannheim Peritonitis Index score [34]. Similarly, several studies have concluded the
increased mortality associated with isolation of Candida [35,36], also in patients with compli-
cated non-postoperative IAIs [32].
The strength of the present prospective descriptive study was the inclusion of all patients
with community-onset severe IAIs admitted in a large number of ICUs in Spain over one year.
Time of source control was not available in our study, this representing a study limitation.
Other inherent limitations of descriptive studies (absence of sample size calculation, variability
in routine laboratory procedures, lack of standardized criteria for hospital discharge. . .) weak-
ness conclusions, although, on the other hand, discloses actual bacterial isolation and thera-
peutic management of this entity in clinical practice. Importantly, the analysis of the empirical
treatments selected by treating physicians suggests an influence of the awareness of possible
resistance in certain patients, since there was a more frequent utilization of broad-spectrum
antibiotics in the HCAI and ICP groups. This could have negatively influenced the multivari-
ate analysis for AMR and 30-day mortality. In this context, the lack of assessment of the ade-
quacy of empirical antimicrobial treatments represents a study limitation, although without
influence on epidemiological AMR results.
Conclusion
Despite AMR (as defined in the present study) were not isolated from ICP patients (possibly
due to the reduced number of ICP cases included), the results of this study showed that the
antimicrobial susceptibility pattern of bacteria isolated from patients with healthcare contact
was shifted to resistance, suggesting the need for consideration of the healthcare category (not
including hospital-acquired infections) for severe IAIs. According to our results, treating phy-
sicians facing the management of severe IAIs should consider not only the patient’s age and
Table 6. Significant data in two-group data analysis.
Variable Survivors
(n = 279)
Dead
(n = 45)
p
Age >75 years 77 (27.6) 31 (68.9) <0.001
HCAIa 50 (17.9) 15 (33.3) 0.017
Small bowel as site of infection 29 (10.4) 12 (26.7) 0.002
Biliary tract as site of infection 60 (21.5) 1 (2.2) 0.002
Appendix as site of infection 55 (19.7) 3 (6.7) 0.034
Generalized peritonitis 132 (47.3) 31 (68.9) 0.007
Localized peritonitis 93 (33.3) 5 (11.1) 0.003
Congestive heart disease 14 (5.0) 8 (17.8) 0.005
Chronic renal failure 18 (6.5) 10 (22.2) 0.002
Lactate�3 mmol/l 59 (21.1) 20 (44.4) 0.001
SAPS IIb >46 points 63 (22.6) 32 (71.1) <0.001
Isolation of CPEc from peritoneal fluid 2 (0.7) 3 (6.7) 0.021
Isolation of Enterobacter spp. from peritoneal fluid 5 (1.8) 4 (8.9) 0.024
Isolation of Candida spp. from peritoneal fluid 40 (14.3) 13 (28.9) 0.027
Variables (values at admission) introduced in the multivariate model for the HCAIa + CAIa population based on the
significant (p<0.05) differences between survivors and dead patients. Data expressed as n (%).
aHCAI: Healthcare-associated infection; CAI: Community-associated infection
bSAPS II: Simplified Acute Physiologic Score-II
cCPE: carbapenemase-producing Enterobacteria
https://doi.org/10.1371/journal.pone.0223092.t006
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severity at admission (risk factors for mortality) but also healthcare exposure as risk factor for
multidrug resistance even in IAIs having community-onset.
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queiro, Vigo, Spain), Garcı́a-Bernedo C., Benı́tez-Cano A., Carazo-Cordobés J., Castelltort
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Lead author for this group: Emilio Maseda, MD PhD; email: emilio.maseda@gmail.com
Author Contributions
Conceptualization: Emilio Maseda, Alejandro Suárez-de-la-Rica.
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